Clinical trials: Degenerative Conditions, Neurologic
PIK3CA-Related Overgrowth Spectrum (PROS)
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib
The study was a site-based retrospective non-interventional medical chart review of pediatric and adult male and female patients with PIK3CA-Related Overgrowth Spectrum (PROS) who initiated alpelisib at least 24 weeks before the…
- Trial name
- EPIK-P1 (NCT04285723)
- Testing
- alpelisib
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
- Trial name
- NCT00568776
- Testing
- ELND005
- Where
- 62 sites in United States, Canada
- Volunteers
- 353 people
- Sponsor
- OPKO Health, Inc.
Low Back Pain
Internet App to Self-Manage Occasional Low Back Pain
Nonspecific low back pain (NLBP) is the diagnosis for 85% of low back pain sufferers with no underlying medical cause (e.g., herniated disc, spinal stenosis) that requires physician care.
- Trial name
- BackPain2 (NCT01950091)
- Testing
- FitBack on-line intervention, Alternative Website Control
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Alzheimer's Disease
Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010) administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed Alzheimer's type disease.
- Trial name
- NCT00976118
- Testing
- masitinib (AB1010)
- Volunteers
- 34 people
- Sponsor
- AB Science
Dementia, Alzheimer's Disease
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal…
- Trial name
- REMIND (NCT00283725)
- Testing
- No intervention
- Volunteers
- 573 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Covid19
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
- Trial name
- NCT04584710
- Testing
- RTB101
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restorbio Inc.
Juvenile Neuronal Ceroid Lipofuscinosis
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.
- Trial name
- NCT04637282
- Testing
- PLX-200
- Sponsor
- Polaryx Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as…
- Trial name
- NCT07223723
- Testing
- Tofersen
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Biogen
Alzheimer's Disease
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks.
- Trial name
- NCT00890890
- Testing
- Avagacestat
- Where
- 64 sites in United States, Canada and 4 more
- Volunteers
- 263 people
- Sponsor
- Bristol-Myers Squibb
Parkinson's Disease
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is tolerated when given at different doses to patients with early-stage Parkinson's Disease.
- Trial name
- MOBILE (NCT00442780)
- Testing
- BIIB014
- Where
- 10 sites in Israel, Poland and 1 more
- Volunteers
- 36 people
- Sponsor
- Biogen
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD).
- Trial name
- NCT00063310
- Testing
- Leuprolide acetate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Voyager Pharmaceutical Corporation
Spinal Muscular Atrophy (SMA)
A Study of the Safety and Preliminary Efficacy of NKG001 in Pediatric Patients With Type 1 or Type 2 Spinal Muscular Atrophy
This study is a single-center, open-label, single-arm, non-randomized, single-dose, dose-escalation investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of NKG001 Injection…
- Trial name
- NCT07617779
- Testing
- NKG001
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nikegen Pharmaceutical (Hangzhou) Company Limited
Parkinson Disease
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease
This study consists of two parts. Part A will evaluate the safety and tolerability of multiple doses of OXB-102 (AXO-Lenti-PD) in participants with Parkinson's disease.
- Trial name
- SUNRISE-PD (NCT03720418)
- Testing
- OXB-102, Imitation Surgical Procedure (ISP)
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 6 people
- Sponsor
- Sio Gene Therapies
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
Virtual Reality Cognitive Therapy for Alzheimer's Disease
To evaluate the usability, feasibility, and acceptability of VRCT iteratively on 36 AD/ADRD individuals with mild to moderate CI.
- Trial name
- VRCT (NCT05788848)
- Testing
- VRCT
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Claritytek, Inc.
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Parkinson Disease
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
This study is to evaluate the safety and tolerability and to characterize the pharmacokinetics of multiple ascending dose (MAD) of LY03003 following intramuscular injections.
- Trial name
- NCT04045678
- Testing
- LY03003 ( Rotigotine, extended-release microspheres)
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Luye Pharma Group Ltd.
Wilson Disease
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy…
- Trial name
- NCT04884815
- Testing
- UX701, Standard of Care (SOC)
- Where
- 16 sites in United States, Portugal and 2 more
- Volunteers
- 82 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.